InsilicoX Co., Ltd.
↗Seoul, South Korea
InsilicoX is a South Korean biotechnology company specializing in AI-driven drug discovery. The company leverages large-scale life-science datasets and bioinformatics to conduct disease prediction, target discovery, and candidate screening.
InsilicoX is actively involved in national R&D initiatives, including the Korean government's 'K-AI Preclinical and Clinical Model Development Program'. They collaborate with major institutions such as Seoul National University Hospital, Samsung Medical Center, and the Korea Research Institute of Bioscience and Biotechnology (KRIBB) to develop AI models aimed at replacing animal studies and enhancing predictive validation in drug development.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Ownership:private
Status:operating
FUNDING
Investors:HEM Pharma
PIPELINE
Stage:Discovery
Lead Drug Stage:Discovery
Modalities:Small molecule, AI-based predictive modeling
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:HEM Pharma (Microbiome drug discovery collaboration), Seoul National University Hospital (AI model development), Samsung Medical Center (AI model development), Korea Research Institute of Bioscience and Biotechnology (KRIBB) (AI model development), Omphalos Lifesciences (AI-driven drug discovery consortium)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Jung Dae-sik - CEO
LINKS
Website:insilicox.co.kr
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of InsilicoX Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with InsilicoX Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.